Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Clinical improvement -2% primary Days to clinical improvem.. -6% Viral clearance 44% c19early.org/a Alattar et al. Favipiravir for COVID-19 EARLY Is early treatment with favipiravir beneficial for COVID-19? PSM retrospective 774 patients in Qatar (May - July 2020) Improved viral clearance with favipiravir (p=0.0000014) Alattar et al., J. Infection and Public Health, doi:10.1016/j.jiph.2022.08.011 Favors favipiravir Favors control
Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study
Alattar et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011 (date from earlier preprint)
Alattar et al., Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011 (date from earlier preprint)
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective with 1,493 patients, showing significantly improved viral clearance with favipiravir. There were no significant differences in clinical improvement or mortality. Mortality was lower (2.1% vs 3.1%), without statistical significance with the small number of events.
risk of death, 33.3% lower, RR 0.67, p = 0.50, treatment 8 of 387 (2.1%), control 12 of 387 (3.1%), NNT 97, propensity score matching.
risk of no clinical improvement, 2.2% higher, RR 1.02, p = 0.73, treatment 26 of 387 (6.7%), control 28 of 387 (7.2%), NNT 194, adjusted per study, inverted to make RR<1 favor treatment, day 28, Cox proportional hazards, propensity score matching, primary outcome.
days to clinical improvement, 6.2% higher, relative time 1.06, p = 0.07, treatment 387, control 387, propensity score matching.
risk of no viral clearance, 43.9% lower, RR 0.56, p < 0.001, treatment 78 of 387 (20.2%), control 139 of 387 (35.9%), NNT 6.3, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alattar et al., 30 Nov 2021, retrospective, Qatar, peer-reviewed, median age 46.0, 25 authors, study period 23 May, 2020 - 18 July, 2020, average treatment delay 5.0 days.
Contact: aomrani@hamad.qa.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Journal Pre-proof Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Scorematched Cohort Study Rand A. Alattar, Shiema Abdalla, Tasneem Abdallah, Rashid Kazman, Aseelah Qadmour, Tawheeda Ibrahim, Bassem Alhariri, Shahd H. Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi, Fatma Ben Abid, Joanne Daghfal, Ali Eldeeb, Kinda Shukri, Ahmed Elsayed, Fatima Rustom, Musaed Alsamawi, Alaaeldin Abdelmajid, Miguel A.P. Basulto, Armando A.R. Cobian, Mohamed Abukhattab, Abdullatif Alkhal, Muna A. Almaslamani, Ali S. Omrani PII: S1876-0341(22)00212-X DOI: https://doi.org/10.1016/j.jiph.2022.08.011 Reference: JIPH1913 To appear in: Journal of Infection and Public Health Received date: 2 June 2022 Revised date: 21 July 2022 Accepted date: 21 August 2022 Please cite this article as: Rand A. Alattar, Shiema Abdalla, Tasneem Abdallah, Rashid Kazman, Aseelah Qadmour, Tawheeda Ibrahim, Bassem Alhariri, Shahd H. Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi, Fatma Ben Abid, Joanne Daghfal, Ali Eldeeb, Kinda Shukri, Ahmed Elsayed, Fatima Rustom, Musaed Alsamawi, Alaaeldin Abdelmajid, Miguel A.P. Basulto, Armando A.R. Cobian, Mohamed Abukhattab, Abdullatif Alkhal, Muna A. Almaslamani and Ali S. Omrani, Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study, Journal of Infection and Public Health, (2022) doi:https://doi.org/10.1016/j.jiph.2022.08.011 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier. Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study Rand A. Alattar,1 Shiema Abdalla,1 Tasneem Abdallah,1 Rashid Kazman,2 Aseelah Qadmour,2 Tawheeda Ibrahim,1 Bassem Alhariri,2 Shahd H. Shaar,1 Abeer Bajwa,1 Abeir Alimam,1 Rabia Qazi,1 Fatma Ben Abid,1,3 Joanne Daghfal,1 Ali Eldeeb,3 Kinda Shukri,3 Ahmed Elsayed,1 Fatima Rustom,1 Musaed Alsamawi,1 Alaaeldin Abdelmajid,1 Miguel A. P. Basulto,4 Armando A. R. Cobian,4 Mohamed Abukhattab,1,3 Abdullatif Alkhal,1,3 Muna A. oo 1 f Almaslamani,1,3 Ali S. Omrani,1,3 Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, e- 2 pr Qatar Doha, Qatar Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar 4 Cuban Hospital, Dukhan, Qatar Jo ur n Dr Ali S. Omrani al Corresponding Author: Pr 3 PO Box 3050 Communicable Disease Center Hamad Medical Corporation Doha, Qatar Telephone: +974 40254329 E-mail: aomrani@hamad.qa Abstract We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥24 hours of favipiravir were assigned to the favipiravir group, while those who did not formed the nonPage 1 of 14 favipiravir group. The primary outcome was 28-day clinical improvement, defined as..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit